203 related articles for article (PubMed ID: 28580443)
1. Reduced Prothrombinase Inhibition by Tissue Factor Pathway Inhibitor Contributes to the Factor V Leiden Hypercoagulable State.
Wood JP; Baumann Kreuziger LM; Ellery PER; Maroney SA; Mast AE
Blood Adv; 2017 Feb; 1(6):386-395. PubMed ID: 28580443
[TBL] [Abstract][Full Text] [Related]
2. Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.
van Doorn P; Rosing J; Campello E; Middeldorp S; Simioni P; Meijers JCM; Hackeng TM; Castoldi E
Thromb Haemost; 2020 Jan; 120(1):55-64. PubMed ID: 31705518
[TBL] [Abstract][Full Text] [Related]
3. TFPIα interacts with FVa and FXa to inhibit prothrombinase during the initiation of coagulation.
Wood JP; Petersen HH; Yu B; Wu X; Hilden I; Mast AE
Blood Adv; 2017 Dec; 1(27):2692-2702. PubMed ID: 29291252
[TBL] [Abstract][Full Text] [Related]
4. The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg
van Doorn P; Rosing J; Wielders SJ; Hackeng TM; Castoldi E
J Thromb Haemost; 2017 Jan; 15(1):140-149. PubMed ID: 27801970
[TBL] [Abstract][Full Text] [Related]
5. Activated protein C, protein S, and tissue factor pathway inhibitor cooperate to inhibit thrombin activation.
Li X; Song X; Mahmood DFD; Sim MMS; Bidarian SJ; Wood JP
Thromb Res; 2023 Oct; 230():84-93. PubMed ID: 37660436
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.
Wood JP; Bunce MW; Maroney SA; Tracy PB; Camire RM; Mast AE
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17838-43. PubMed ID: 24127605
[TBL] [Abstract][Full Text] [Related]
7. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S.
Dahlbäck B
J Thromb Haemost; 2017 Jul; 15(7):1241-1250. PubMed ID: 28671348
[TBL] [Abstract][Full Text] [Related]
8. Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.
van Doorn P; Rosing J; Duckers C; Hackeng TM; Simioni P; Castoldi E
Thromb Haemost; 2018 Jul; 118(7):1194-1202. PubMed ID: 29864781
[TBL] [Abstract][Full Text] [Related]
9. Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
Thomassen MC; Heinzmann AC; Herfs L; Hartmann R; Dockal M; Scheiflinger F; Hackeng TM; Rosing J
J Thromb Haemost; 2015 Jan; 13(1):92-100. PubMed ID: 25348176
[TBL] [Abstract][Full Text] [Related]
10. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.
Santamaria S; Reglińska-Matveyev N; Gierula M; Camire RM; Crawley JTB; Lane DA; Ahnström J
J Biol Chem; 2017 Jun; 292(22):9335-9344. PubMed ID: 28420729
[TBL] [Abstract][Full Text] [Related]
11. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III, and heparin cofactor-II.
van 't Veer C; Mann KG
J Biol Chem; 1997 Feb; 272(7):4367-77. PubMed ID: 9020158
[TBL] [Abstract][Full Text] [Related]
12. Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.
Petrillo T; Ayombil F; Van't Veer C; Camire RM
J Biol Chem; 2021; 296():100234. PubMed ID: 33376137
[TBL] [Abstract][Full Text] [Related]
13. Role of exosite binding modulators in the inhibition of Fxa by TFPI.
Peraramelli S; Thomassen S; Heinzmann A; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M; Rosing J
Thromb Haemost; 2016 Mar; 115(3):580-90. PubMed ID: 26607136
[TBL] [Abstract][Full Text] [Related]
14. Lethal perinatal thrombosis in mice resulting from the interaction of tissue factor pathway inhibitor deficiency and factor V Leiden.
Eitzman DT; Westrick RJ; Bi X; Manning SL; Wilkinson JE; Broze GJ; Ginsburg D
Circulation; 2002 May; 105(18):2139-42. PubMed ID: 11994245
[TBL] [Abstract][Full Text] [Related]
15. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.
van 't Veer C; Hackeng TM; Delahaye C; Sixma JJ; Bouma BN
Blood; 1994 Aug; 84(4):1132-42. PubMed ID: 8049429
[TBL] [Abstract][Full Text] [Related]
16. Factor V east Texas variant causes bleeding in a three-generation family.
Peterson JA; Gupta S; Martinez ND; Hardesty B; Maroney SA; Mast AE
J Thromb Haemost; 2022 Mar; 20(3):565-573. PubMed ID: 34847292
[TBL] [Abstract][Full Text] [Related]
17. New insights into the biology of tissue factor pathway inhibitor.
Maroney SA; Mast AE
J Thromb Haemost; 2015 Jun; 13 Suppl 1(0 1):S200-7. PubMed ID: 26149025
[TBL] [Abstract][Full Text] [Related]
18. Protein Z-dependent protease inhibitor (ZPI) is a physiologically significant inhibitor of prothrombinase function.
Huang X; Swanson R; Kroh HK; Bock PE
J Biol Chem; 2019 May; 294(19):7644-7657. PubMed ID: 30918026
[TBL] [Abstract][Full Text] [Related]
19. The procoagulant effects of factor V Leiden may be balanced against decreased levels of factor V and do not reflect in vivo thrombin formation in newborns.
Hyytiäinen S; Wartiovaara-Kautto U; Ulander VM; Kaaja R; Heikinheimo M; Petäjä J
Thromb Haemost; 2006 Mar; 95(3):434-40. PubMed ID: 16525570
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)α and TFPIβ.
Maroney SA; Ellery PE; Wood JP; Ferrel JP; Martinez ND; Mast AE
J Thromb Haemost; 2013 May; 11(5):911-8. PubMed ID: 23480518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
